DB-1303/BNT323
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for DB-1303/BNT323, covering 2025-10-20 to 2026-06-02. Get the full timeline:
Most recent: Clinical Trial Update: A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) [Phase 3]